Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prodrugs01:30

Prodrugs

4.0K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.0K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

249
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
249
Principles of Drug Action01:24

Principles of Drug Action

8.1K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
8.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.1K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dual-Scandium-Capped Boron Cage: Structural and Electronic Properties of B<sub>10</sub>Sc<sub>2</sub>.

ACS omega·2026
Same author

Development and internal validation of a nomogram for predicting the severity of community-acquired pneumonia in children.

Frontiers in cellular and infection microbiology·2026
Same author

Expression and clinical significance of miR-223 in children with severe pneumonia.

Scientific reports·2026
Same author

Engineered photothermal-responsive bacterial platform for in vivo fluorescence imaging-guided photothermal/gene combined breast cancer therapy.

Trends in biotechnology·2026
Same author

Post-Synthetic Modification of the C═C Linkage in a Vinylene-Linked COF for ROS-Mediated Enamine Dimerization.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Age-dependent starch-sucrose metabolic transition during bulb development of Fritillaria unibracteata.

BMC plant biology·2026

相关实验视频

Updated: Jan 14, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.5K

德克萨米他附加的可激活原药克服多药物耐药性

Jungryun Kim1, Chong Hu2, Paramesh Jangili1

  • 1Department of Chemistry, Korea University, Seoul 02841, Korea.

Journal of medicinal chemistry
|October 23, 2025
PubMed
概括

这项研究开发了Dex-Dox,这是一种克服化疗耐药性的新型前药. 在耐药模型中,Dex-Dox有效降低了瘤体积,为癌症治疗提供了一个有前途的策略.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K

相关实验视频

Last Updated: Jan 14, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K

科学领域:

  • 在瘤学瘤学.
  • 药物开发 药物开发
  • 生物化学 生物化学

背景情况:

  • 化疗后的残留瘤细胞经常表现出多药性耐药性 (MDR) 和侵入性增加,导致转移和复发.
  • 克服MDR对于改善癌症治疗疗效和患者治疗结果至关重要.

研究的目的:

  • 开发和评估一种新型反应性氧物种 (ROS) 响应的前药物Dex-Dox,用于克服瘤细胞中的MDR.
  • 评估Dex-Dox在耐药癌症模型中的体外和体内疗效.

主要方法:

  • 通过氧化应激反应链接剂将德克萨米他 (Dex) 与多克索鲁比 (Dox) 结合在一起,形成Dex-Dox前药物.
  • 在体外评估Dex-Dox对耐药细胞的影响,包括诱导细胞亡和抗血管生成活性.
  • 在Dox耐药瘤小鼠模型中的体内治疗评估和组织学分析.

主要成果:

  • 德克斯-多克斯显著增强了药物敏感性,促进了细胞亡,并抑制了耐药细胞的血管生成in vitro.
  • 在体内研究表明,Dex-Dox显著降低了瘤体积,特别是在对Dox耐药的小鼠模型中.
  • 德克萨米他单独没有表现出抗瘤活性,突出显示了前药物的特定机制.

结论:

  • 德克斯-多克斯是一种强大的ROS响应性前药,有效对抗多药耐药癌细胞.
  • 这些发现强调了Dex-Dox作为一种创新的治疗策略的潜力,用于打击癌症治疗中的MDR.
  • 对Dex-Dox的进一步调查可能会导致耐药瘤患者的临床结果得到改善.